Evaluation of T cell responses to naturally processed variant SARS-CoV-2 spike antigens in individuals following infection or vaccination

评估感染或接种疫苗后个体对天然加工的SARS-CoV-2变异刺突抗原的T细胞反应。

阅读:3
作者:Zixi Yin,Ji-Li Chen,Yongxu Lu,Beibei Wang,Leila Godfrey,Alexander J Mentzer,Xuan Yao,Guihai Liu,Dannielle Wellington,Yiqi Zhao,Peter A C Wing,Wanwisa Dejnirattisa,Piyada Supasa,Chang Liu,Philip Hublitz,Ryan Beveridge,Craig Waugh,Sally-Ann Clark,Kevin Clark,Paul Sopp,Timothy Rostron,Juthathip Mongkolsapaya,Gavin R Screaton,Graham Ogg,Katie Ewer,Andrew J Pollard,Sarah Gilbert,Julian C Knight,Teresa Lambe,Geoffrey L Smith,Tao Dong,Yanchun Peng  0

Abstract

Most existing studies characterizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell responses are peptide based. This does not allow evaluation of whether tested peptides are processed and presented canonically. In this study, we use recombinant vaccinia virus (rVACV)-mediated expression of SARS-CoV-2 spike protein and SARS-CoV-2 infection of angiotensin-converting enzyme (ACE)-2-transduced B cell lines to evaluate overall T cell responses in a small cohort of recovered COVID-19 patients and uninfected donors vaccinated with ChAdOx1 nCoV-19. We show that rVACV expression of SARS-CoV-2 antigen can be used as an alternative to SARS-CoV-2 infection to evaluate T cell responses to naturally processed spike antigens. In addition, the rVACV system can be used to evaluate the cross-reactivity of memory T cells to variants of concern (VOCs) and to identify epitope escape mutants. Finally, our data show that both natural infection and vaccination could induce multi-functional T cell responses with overall T cell responses remaining despite the identification of escape mutations.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。